Management of metastatic esophagogastric junction adenocarcinoma

Tasuku Toihata, Yu Imamura, Masayuki Watanabe, Hideo Baba
2018 Journal of Cancer Metastasis and Treatment  
How to cite this article: Toihata T, Imamura Y, Watanabe M, Baba H. Management of metastatic esophagogastric junction adenocarcinoma. J Cancer Metastasis Treat 2018;4:24. http://dx. Abstract The prognosis of metastatic disease of esophagogastric junction adenocarcinoma remains poor, despite using a variety of regimens using cytotoxic agents. Recent understanding of molecular characteristic and tumor microenvironment of this cancer is currently instigating new therapeutic options. In this
more » ... ons. In this review, we summarized previous evidences of cytotoxic agents widely used worldwide, and updated recent developments of molecular targeted drugs, and immune checkpoint inhibitors.
doi:10.20517/2394-4722.2017.82 fatcat:p2zqjetl7jcojmdicrq7chzlle